SE503279C2 - Vattenlösliga monoestrar som solubiliseringsmedel för farmakologiskt aktiva föreningar och farmaceutiska excipienter - Google Patents

Vattenlösliga monoestrar som solubiliseringsmedel för farmakologiskt aktiva föreningar och farmaceutiska excipienter

Info

Publication number
SE503279C2
SE503279C2 SE8803221A SE8803221A SE503279C2 SE 503279 C2 SE503279 C2 SE 503279C2 SE 8803221 A SE8803221 A SE 8803221A SE 8803221 A SE8803221 A SE 8803221A SE 503279 C2 SE503279 C2 SE 503279C2
Authority
SE
Sweden
Prior art keywords
water
monoester
solution
solid solution
soluble
Prior art date
Application number
SE8803221A
Other languages
English (en)
Swedish (sv)
Other versions
SE8803221L (sv
SE8803221D0 (sv
Inventor
Lorenz Hahn
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of SE8803221D0 publication Critical patent/SE8803221D0/xx
Publication of SE8803221L publication Critical patent/SE8803221L/
Publication of SE503279C2 publication Critical patent/SE503279C2/sv

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SE8803221A 1987-09-15 1988-09-13 Vattenlösliga monoestrar som solubiliseringsmedel för farmakologiskt aktiva föreningar och farmaceutiska excipienter SE503279C2 (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3730909 1987-09-15
DE3802355 1988-01-27

Publications (3)

Publication Number Publication Date
SE8803221D0 SE8803221D0 (sv) 1988-09-13
SE8803221L SE8803221L (sv) 1989-03-16
SE503279C2 true SE503279C2 (sv) 1996-05-13

Family

ID=25859774

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8803221A SE503279C2 (sv) 1987-09-15 1988-09-13 Vattenlösliga monoestrar som solubiliseringsmedel för farmakologiskt aktiva föreningar och farmaceutiska excipienter

Country Status (24)

Country Link
JP (1) JP3090666B2 (fi)
KR (1) KR0131084B1 (fi)
AT (1) AT395819B (fi)
AU (1) AU628787B2 (fi)
BE (1) BE1001204A5 (fi)
CA (1) CA1338775C (fi)
CH (1) CH683672A5 (fi)
DK (1) DK175132B1 (fi)
ES (1) ES2012118A6 (fi)
FI (1) FI94837C (fi)
FR (1) FR2620336B1 (fi)
GB (1) GB2209671B (fi)
GR (1) GR1002243B (fi)
HU (1) HU205010B (fi)
IE (1) IE61195B1 (fi)
IL (1) IL87746A (fi)
IT (1) IT1224886B (fi)
LU (1) LU87335A1 (fi)
MY (1) MY103769A (fi)
NL (1) NL195094C (fi)
NO (1) NO179434C (fi)
NZ (1) NZ226163A (fi)
PT (1) PT88492B (fi)
SE (1) SE503279C2 (fi)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0148748B1 (ko) 1988-09-16 1998-08-17 장 크라메르, 한스 루돌프 하우스 사이클로스포린을 함유하는 약학조성물
US6007840A (en) * 1988-09-16 1999-12-28 Novartis Ag Pharmaceutical compositions comprising cyclosporins
GR1000466B (el) * 1989-01-28 1992-07-30 Sandoz Ag Μεθοδος παρασκευης νεων φαρμακευτικων μορφων κυκλοσπορινης.
CH679277A5 (fi) * 1989-02-09 1992-01-31 Sandoz Ag
GB8916901D0 (en) 1989-07-24 1989-09-06 Sandoz Ltd Improvements in or relating to organic compounds
US6262022B1 (en) 1992-06-25 2001-07-17 Novartis Ag Pharmaceutical compositions containing cyclosporin as the active agent
SG45449A1 (en) 1992-05-13 1998-01-16 Sandoz Ltd Ophthalmic compositions
EP1142568A1 (en) 1992-09-25 2001-10-10 Novartis AG Pharmaceutical compositions containing cyclosporins
SI1033128T2 (sl) 1993-09-28 2012-02-29 Scherer Gmbh R P Izdelava mehke Ĺľelatinaste kapsule
ES2177652T3 (es) 1994-11-03 2002-12-16 Novartis Ag Nuevas formas de preparacion de ciclosporina para la aplicacion oral con composicion simple y alta biodisponibilidad, y procedimiento para su obtencion.
US5766629A (en) * 1995-08-25 1998-06-16 Sangstat Medical Corporation Oral cyclosporin formulations
US5962019A (en) * 1995-08-25 1999-10-05 Sangstat Medical Corporation Oral cyclosporin formulations
US5827822A (en) * 1996-03-25 1998-10-27 Sangstat Medical Corporation Cyclosporin a formulations as nanoparticles
US5834017A (en) * 1995-08-25 1998-11-10 Sangstat Medical Corporation Oral cyclopsporin formulations
DE19544507B4 (de) 1995-11-29 2007-11-15 Novartis Ag Cyclosporin enthaltende Präparate
TW414696B (en) * 1996-07-01 2000-12-11 Mitsubishi Kagaku Foods Kk Anti-bacteria agent
AU737053B2 (en) 1997-01-30 2001-08-09 Novartis Ag Oil-free pharmaceutical compositions containing cyclosporin A
GB2326337A (en) * 1997-06-20 1998-12-23 Phares Pharma Holland Homogeneous lipid compositions for drug delivery
US7732404B2 (en) 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
EP1558215A4 (en) * 2003-10-14 2007-09-12 Wockhardt Ltd STERILE GELIFYING AGENTS
JP5422871B2 (ja) * 2006-10-24 2014-02-19 不二製油株式会社 イソフラボン類組成物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL284933A (fi) * 1961-10-31
GB1134878A (en) * 1966-05-12 1968-11-27 Suga Kazuo Improvements in and relating to oryzanol solutions and compositions
FR5986M (fi) * 1966-11-22 1968-06-21
BE787842A (fr) * 1971-08-25 1972-12-18 Sumito Chemical Cy Ltd Procede de preparation d'une suspension aqueuse de cristaux stables du type non beta d'esters d'acides gras superieurs du chloramphenicol
JPS53107408A (en) * 1977-02-28 1978-09-19 Yamanouchi Pharmaceut Co Ltd Micellar preparation for rectal infusion
DE2907460A1 (de) * 1978-03-07 1979-09-13 Sandoz Ag Neue resorbierbare galenische kompositionen
JPS57128634A (en) * 1981-02-03 1982-08-10 Eisai Co Ltd Elastase-containing compound increasing absorption
EP0179583A1 (en) * 1984-10-04 1986-04-30 Merck & Co. Inc. A system for enhancing the water dissolution rate and solubility of poorly soluble drugs
JPS61280435A (ja) * 1985-04-04 1986-12-11 Kanji Takada サイクロスポリン類のリンパ指向性製剤

Also Published As

Publication number Publication date
NO179434B (no) 1996-07-01
HUT49494A (en) 1989-10-30
JPH01151526A (ja) 1989-06-14
ES2012118A6 (es) 1990-03-01
HU205010B (en) 1992-03-30
IE61195B1 (en) 1994-10-19
LU87335A1 (fr) 1989-04-06
NO884052L (no) 1989-03-16
AU628787B2 (en) 1992-09-24
DK511188D0 (da) 1988-09-14
IT8848349A0 (it) 1988-09-14
IE882772L (en) 1989-03-15
IL87746A (en) 1992-07-15
BE1001204A5 (fr) 1989-08-16
IT1224886B (it) 1990-10-24
GB8821443D0 (en) 1988-10-12
KR890004694A (ko) 1989-05-09
MY103769A (en) 1993-09-30
GR1002243B (en) 1996-04-22
FI94837C (fi) 1995-11-10
SE8803221L (sv) 1989-03-16
IL87746A0 (en) 1989-02-28
PT88492B (pt) 1993-03-31
GB2209671B (en) 1991-11-13
FR2620336A1 (fr) 1989-03-17
FI94837B (fi) 1995-07-31
CH683672A5 (de) 1994-04-29
PT88492A (pt) 1988-10-01
FI884192A0 (fi) 1988-09-13
GR880100602A (el) 1989-06-22
NO179434C (no) 1996-10-09
KR0131084B1 (ko) 1998-04-17
NO884052D0 (no) 1988-09-13
NZ226163A (en) 1991-08-27
JP3090666B2 (ja) 2000-09-25
FR2620336B1 (fr) 1991-10-25
DK511188A (da) 1989-03-16
CA1338775C (en) 1996-12-10
NL8802275A (nl) 1989-04-03
GB2209671A (en) 1989-05-24
AU2217288A (en) 1989-04-27
ATA224988A (de) 1992-08-15
NL195094C (nl) 2003-12-17
SE8803221D0 (sv) 1988-09-13
DK175132B1 (da) 2004-06-14
FI884192A (fi) 1989-03-16
AT395819B (de) 1993-03-25

Similar Documents

Publication Publication Date Title
US5756450A (en) Water soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients and novel cyclosporin galenic forms
SE503279C2 (sv) Vattenlösliga monoestrar som solubiliseringsmedel för farmakologiskt aktiva föreningar och farmaceutiska excipienter
EP0863765B1 (en) Pharmaceutical compositions of cyclosporine with a polyethoxylated saturated hydroxy-fatty acid
JP4073503B2 (ja) サイクロスポリンを含有する液体製剤とその調製方法
CA1341396C (en) Cyclosporin crystal form, processes for its production pharmaceutical compositions containing it and its use
SE511398C2 (sv) Komposition innehållande cyklosporin och sackaros- eller raffinosmonolaurat
US6187747B1 (en) Pharmaceutical composition comprising cyclosporin
JP2003507343A (ja) 経口及び局所投与用の医薬組成物
EP0985412B1 (en) Cyclosporin compositions
US6008191A (en) Pharmaceutical compositions containing cyclosporin
EP1151755B1 (en) Pharmaceutical compositions comprising cyclosporin as active ingredient
JP2942556B2 (ja) シクロスポリンを含有する新規組成物
US6346511B1 (en) Pharmaceutical composition comprising cyclosporin
DE3830494B4 (de) Wasserlösliche Monoester als Solubilisatoren für pharmakologische Wirkstoffe und pharmazeutische Hilfsstoffe
KR0173349B1 (ko) 사이클로스포린-함유 고체 분산체 조성물
RU2207870C2 (ru) Фармацевтическая композиция, включающая циклоспорин в качестве активного ингредиента

Legal Events

Date Code Title Description
NUG Patent has lapsed